Sunshine Biopharma Inc. announced today that it has completed additional studies on orthotopic human tumor models in mice, confirming its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) product as a therapeutic agent for human hepatocellular carcinoma. Human hepatocellular carcinoma (HCC) is identified as the third leading cause of cancer-related deaths worldwide and is the most common type of primary liver cancer in adults. This preclinical advancement marks a significant step in the company's oncology pipeline.
The studies demonstrated that K1.1-mRNA-LNP was efficiently delivered to orthotopic engrafted HCC tumors in mice in a dose-dependent manner through systemic administration. Under repeated dosing, the full-length K1.1c reduced the growth of three different types of human HCC tumors in mice with good tolerability. This indicates the potential of K1.1 mRNA as a targeted and effective treatment.
A proof-of-concept study for a smaller, truncated version, K1.1d, also suggested significant, dose-dependent anti-tumor activity in mouse HCC models. The company is conducting further animal studies to optimize dosing for K1.1d, which offers the advantage of potentially better efficacy at lower doses. These findings support the long-term value proposition of SBFM's innovative drug development programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.